Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2026 16:15 ET | Source: Chemed Corp.

Chemed Reports Fourth-Quarter 2025 Results

CINCINNATI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), the nation’s largest providers of end-of-life care, and...
February 25, 2026 12:54 ET | Source: BCC Research LLC

Advanced Drug Delivery Market to Grow 10.2% Annually Through 2030

“Global Markets and Technologies for Advanced Drug Delivery Systems - Focus on Routes of Administration” is projected to grow at CAGR of 10.2% from 2025-30
February 25, 2026 08:30 ET | Source: Sutro Biopharma, Inc.

Sutro Biopharma to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
February 24, 2026 16:00 ET | Source: Day One Biopharmaceuticals, Inc.

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

Day One reports fourth quarter and full year 2025 financial results and reaffirms 2026 outlook and revenue guidance
February 24, 2026 07:30 ET | Source: Promatix Biosciences, Ltd.

Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate...
February 24, 2026 07:02 ET | Source: Cavli Inc

Cavli CQM220 5G RedCap Module: Compact and Cost-Optimized 5G Connectivity for Next-Generation IoT Applications

Cavli highlights the CQM220 5G RedCap module, combining high-speed 5G, dual-band GNSS, OpenWrt with SDK, LTE fallback, and global IoT scalability.
February 24, 2026 02:00 ET | Source: Avacta Group PLC

Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu® Clinical trial with AVA6103 is expected to be initiated...
February 23, 2026 17:10 ET | Source: Kyntra Bio

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer...
February 23, 2026 08:50 ET | Source: Akari Therapeutics Plc

Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel...
February 23, 2026 08:30 ET | Source: Sutro Biopharma, Inc.

Sutro Biopharma Announces Participation at the 16th World ADC London Summit

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...